The United Kingdom and the United States have announced a key bilateral deal that will preserve no levies on British pharmaceutical exports entering the American market.
The Terms of the Deal
As part of the deal, the UK has agreed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that import taxes on these key products will remain at zero for a timeframe of 36 months.
This development is in response to recent statements to significantly raise duties on patented drug products, with figures floated reaching one hundred percent.
"This agreement with the United Kingdom reinforces the international landscape for new treatments and establishes long-overdue fairness to American-British drug exports," a statement declared.
Trade Impact
Medicines are one of the UK's most significant exports to the US, which is easily the biggest buyer for major UK drugmakers.
Statistics reveal that in the year leading up to the third quarter, the UK exported pharmaceutical products totaling billions to the US. This value accounted for 17.4% of all goods exports in that timeframe.
"This guarantee protects jobs, increases funding and paves the way for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary commented.
Specific UK Commitments
The agreement involves several key pledges from the British government:
- Price Threshold Increase: The UK will increase the affordability limit at which it judges new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to raise overall NHS spending on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Payback Limit: The amount manufacturers must pay back to the NHS to prevent overspending will be restricted at fifteen percent. Last year, repayments topped 20%.
Industry Background
This agreement comes amid a long-running row between the sector and the British authorities over drug pricing and NHS adoption.
These tensions were heightened by assertions that US customers were paying several times more for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been delayed or scrapped, while substantial funding commitments have been announced toward American operations.
A senior figure publicly accepted that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a proportion of its total funding over the last ten years.
